title: Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure.
authors.forename: Takashi
authors.initials: T
authors.lastname: Onaka
authors.forename: Naoto
authors.initials: N
authors.lastname: Takahashi
authors.forename: Masatomo
authors.initials: M
authors.lastname: Miura
authors.forename: Akihito
authors.initials: A
authors.lastname: Yonezawa
authors.forename: Kazunori
authors.initials: K
authors.lastname: Imada
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sawada
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001549:Benzamides; D003928:Diabetic Nephropathies / Q000628:therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D000068877:Imatinib Mesylate; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000188:drug therapy*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D007690:Polycystic Kidney Diseases / Q000150:complications; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib